Interviews
Zak Mir talks to Tim McCarthy, Chairman and CEO, Immupharma, about the recent fund raise, highlights of the company’s portfolio, and the main focus of its drug discovery and development strategy – 22 September 2023
ImmuPharma “absolutely delighted” to push on with new clinical trial – 28 June 2023
Tim McCarthy, CEO of ImmuPharma talks to Proactive Investors on the recent positive guidance from the FDA on its autoimmune program, CIDP – 24 May 2023
Tim McCarthy, CEO talks to Proactive on recent positive newsflow and his optimism on the forthcoming FDA meetings for Lupuzor for lupus and CIDP – 27 April 2023
Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor on recent news which confirms that Lupuzor will move into a Phase 2/3 adaptive study in H2 2023 – February 2023
Dr Martin Hall, Analyst at Stanford Capital Partners, talks to Proactive Investors on the continued inherent value of ImmuPharma and its continued support by its Lupuzor partner, Avion Pharmaceuticals, as they expand their collaboration partnership to potentially bring in near term revenues – 1st December 2022
Tim McCarthy, CEO & Tim Franklin, COO present via the Investor Meet Company platform on the current fundraising, their commitment to commencing the Lupuzor Phase 3 study in 2022 and the overall investment thesis of ImmuPharma – 5th August 2022
Pharmaceutical analyst Dr Martin Hall presents his initiated research on ImmuPharma PLC ahead of next month’s FDA response which, the analyst, expects will trigger the start of Phase 3 for the company’s lead drug Lupuzor – 25 July 2022
ImmuPharma’s CEO, Tim McCarthy, talks to Proactive Investor on commencement of PK study for Lupuzor, on track to deliver results by end Q1, and also plans for progressive news-flow on pipeline over the next period – 8 February 2022
Tim McCarthy, CEO of ImmuPharma, talks to Proactive Investor on the successful £3.55m fundraising, giving validation of new corporate strategy from Lupuzor™ partner Avion Pharmaceuticals – 20 Dec 2021
Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor following the recent Corporate Update, outlining the broadening of the portfolio and re-emphasising the Board’s focus on delivering near term shareholder value on its key assets including moving Lupuzor into its Phase 3 trial – 22 Nov 2021
Tim McCarthy, CEO of ImmuPharma, talks to Proactive Investor on the recent Company ‘Corporate Update’, the refocused product development portfolio and the positive corporate structure changes – 4 October 2021
ImmuPharma’s CEO, Tim McCarthy, talks to Proactive Investor and presents the commercial strategy for the Company’s lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial – 17th August, 2021
ImmuPharma AGM 2021 – Investor Meet Company Presentation. 28 June 2021
Navid Malik, of The Life Sciences Division talks to Proactive Investors on his investment thesis on ImmuPharma and its late stage drug asset, Lupuzor™ as it gears up to start Phase III trials in Lupus patients in H2 2021 – 18 February 2021